NICE approves extra ‘triple therapy’ drug for diabetes
Regulator recommends dapagliflozin in triple therapy
Thursday, 24 November 2016
NICE has published final guidance that recommends dapagliflozin be used for treating type 2 diabetes as part of what it calls “triple therapy”.
Dapagliflozin can now be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.
In cases where a person’s blood glucose levels are not being controlled sufficiently by metformin (or an alternative drug) and an added second drug, patients can be offered a third drug as part of triple therapy.
NICE’s final guidance means that dapagliflozin joins two other similar drugs, empagliflozin and canagliflozin, as NICE-recommended options for triple therapy.
All three drugs are already recommended for use on their own if a person cannot use metformin or other specific drugs, or in combination with metformin as dual therapy.
Professor Carole Longson, director of NICE’s centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs.
“This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.
“And as we’ve been able to publish this final guidance sooner because of positive draft recommendations, we hope that people who need this extra treatment option will benefit more quickly.”